You are here
e-cancer - Discovery offers hope for new cancer treatments
Although they have been used for many years to treat certain tumours, researchers didn't know how they worked until now. The findings, published in EMBO Reports and presented by Cancer Research UK's chief scientist Professor Sir David Lane at the NCRI Cancer Conference in Birmingham on Tuesday, pave the way for the development of a new range of cancer treatments. The study, carried out at the University of Dundee, examined a molecule called NEDD8, known to have important role in turning on p53, the gene which inhibits a cell's growth. p53 is faulty (and sometimes missing) in more than half of cancers.
The team, led by AICR Research Fellow, Dr Dimitris Xirodimas, discovered that blocking the activity of NEDD8 played a crucial part in allowing cancer drugs such as Actinomycin D to be able to switch on p53 - causing the death of the cancer cells.
NEDD8 works by attaching itself to other proteins - a process called NEDDylation - to alter their properties. The Dundee group found that NEDDylation stops certain proteins leaving a specialised area of the cell, impeding this allows the proteins to move and gives the signal for p53 to be activated, killing the cancer cells.
Dr Dimitris Xirodimas said: "We are excited about these findings. A pharmaceutical company has recently developed chemicals which block the NEDDylation reaction and these compounds are currently being tested in clinical trials for the treatment of cancer. Our research reinforces the value of this work and opens up avenues for the development of new ways to treat cancer." The study was funded by AICR, the Association for International Cancer Research (AICR).
The charity's, Scientific Advisor, Dr Mark Matfield said: "The significance of this discovery is that it could lead to drugs that would be effective against a wide range of cancers. Over the last decade, many of the new cancer drugs have only been useful for a few, specific cancers. What we really need are effective broad range cancer therapies." Professor Sir David Lane, Cancer Research UK's chief scientist said: "p53 is missing or faulty in almost half of all cancers and there are 270,000 new cases of cancer in the UK each year so by understanding potential therapies can switch it on and off is an important part of the search for new potential therapies."
Source: Cancer Research UK